Background: Adjuvants have been obtained empirically by trial and error experiments and
today, there is a tendency to the rational design of adjuvants candidates, which will increasingly
achieve effective and safe products. The aim of this work was to design and evaluate the compound
IMR-23 derived from nitroimidazole as an immunomodulatory molecule.
Materials and Methods: The IMR-23 molecule was obtained by a condensation reaction, cytotoxicity
was tested by the sulforhodamine B assay. Adjuvanticity was evaluated in vivo and in vitro in J774A.1
cells and in the mouse model, respectively.
Results: IMR-23 that did not show cytotoxicity on HeLa, Vero cells and macrophages J774A.1, was
able to induce the production of molecules involved in the inflammatory process, such as cytokines and
chemokines determined by ELISA, to induce the production of antibodies and to generate antigenspecific
cells to ovalbumin and against the antigen GST-L1b.
Conclusion: These results open the possibility of further studies to obtain a proper balance of immunogenicity-
toxicity in the use of IMR-23 as an adjuvant molecule.